Accretion PharmaceuticalsNSE:ACCPL -1.81%18 EBITDA Margin % is 17.35% as of Mar. 2026, which is 3% above its 10-year median of 16.89. GuruFocus rates NSE:ACCPL with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Accretion Pharmaceuticals ranks better than 61.15% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Accretion Pharmaceuticals EBITDA Margin % Related Terms
Accretion Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ACCPL vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Pharmaceuticals (NSE:ACCPL) has a EBITDA Margin % of 17.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Accretion Pharmaceuticals and its competitors. This is near median its historical median of 16.89. Over the past decade, Accretion Pharmaceuticals' EBITDA Margin % has ranged from 7.10 to 22.79. According to the industry distribution chart, Accretion Pharmaceuticals ranks #371 out of 955 companies in the Drug Manufacturers industry, placing it in the top 38.8%.
Is Accretion Pharmaceuticals' EBITDA Margin % too high?
Accretion Pharmaceuticals' current EBITDA Margin % of 17.35% is near median its 10-year median of 16.89. Over the past 10 years, this metric has ranged from a low of 7.10 to a high of 22.79. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Accretion Pharmaceuticals' value of 17.35% is 39.5% above this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #371 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Accretion Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #371 out of 955 companies for EBITDA Margin %. This puts Accretion Pharmaceuticals in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Accretion Pharmaceuticals' value of 17.35% is 39.5% above this benchmark. Historically, Accretion Pharmaceuticals' own EBITDA Margin % has ranged from 7.10 to 22.79 over the past decade. While the company's 10-year median is 16.89 vs. the industry median of 12.44, Accretion Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current EBITDA Margin % of 17.35% is 39.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current EBITDA Margin % is 17.35%, which is near median its own 10-year median of 16.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current EBITDA Margin % of 17.35%. The current EBITDA Margin % is 17.35%, which is near median its 10-year median of 16.89 and 39.5% above the Drug Manufacturers industry median of 12.44. Accretion Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current EBITDA Margin % is 17.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
18GF Score
Get the complete analysis for NSE:ACCPL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 